Bum Jun Kim

2.4k total citations
60 papers, 1.1k citations indexed

About

Bum Jun Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Bum Jun Kim has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Bum Jun Kim's work include Pancreatic and Hepatic Oncology Research (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Colorectal Cancer Treatments and Studies (11 papers). Bum Jun Kim is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Colorectal Cancer Treatments and Studies (11 papers). Bum Jun Kim collaborates with scholars based in South Korea, United States and Nigeria. Bum Jun Kim's co-authors include Hyeong Su Kim, Jung Han Kim, Hyun Joo Jang, Dae Young Zang, Heung-Moon Chang, Changhoon Yoo, Baek‐Yeol Ryoo, Kyu‐pyo Kim, Jaewon Hyung and Won Sang Park and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Bum Jun Kim

58 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bum Jun Kim South Korea 18 536 449 337 294 277 60 1.1k
Yiyi Yu China 21 741 1.4× 460 1.0× 447 1.3× 273 0.9× 253 0.9× 99 1.4k
Caterina Vivaldi Italy 18 760 1.4× 512 1.1× 346 1.0× 403 1.4× 207 0.7× 101 1.3k
Xinyu Bi China 17 480 0.9× 289 0.6× 361 1.1× 316 1.1× 400 1.4× 100 1.2k
Dongmei Ji China 15 539 1.0× 463 1.0× 392 1.2× 163 0.6× 120 0.4× 92 1.2k
Alfredo Mellano Italy 12 641 1.2× 207 0.5× 180 0.5× 324 1.1× 166 0.6× 24 917
Dulabh Monga United States 15 539 1.0× 227 0.5× 396 1.2× 277 0.9× 158 0.6× 74 1.1k
Ho-Yeong Lim South Korea 17 345 0.6× 308 0.7× 301 0.9× 173 0.6× 143 0.5× 31 863
Yusuke Mitsunori Japan 19 435 0.8× 225 0.5× 417 1.2× 182 0.6× 252 0.9× 40 1.0k
Marlies Michl Germany 18 697 1.3× 384 0.9× 167 0.5× 222 0.8× 243 0.9× 47 1.1k
Yun-shan Tan China 16 296 0.6× 376 0.8× 190 0.6× 351 1.2× 221 0.8× 52 851

Countries citing papers authored by Bum Jun Kim

Since Specialization
Citations

This map shows the geographic impact of Bum Jun Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bum Jun Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bum Jun Kim more than expected).

Fields of papers citing papers by Bum Jun Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bum Jun Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bum Jun Kim. The network helps show where Bum Jun Kim may publish in the future.

Co-authorship network of co-authors of Bum Jun Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Bum Jun Kim. A scholar is included among the top collaborators of Bum Jun Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bum Jun Kim. Bum Jun Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jung, Han Na, Ji Hye Huh, Eun Youn Roh, et al.. (2025). Risk of pancreatic cancer according to glycemic status in nonalcoholic fatty liver disease: a nationwide cohort study. Scientific Reports. 15(1). 23308–23308.
2.
3.
Sohn, Sung‐Hwa, et al.. (2024). Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment. International Journal of Molecular Sciences. 25(3). 1769–1769. 1 indexed citations
4.
Kim, Chang Gon, Minkyu Jung, Hyo Song Kim, et al.. (2023). Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer. Journal of Clinical Oncology. 41(27). 4394–4405. 27 indexed citations
5.
Lee, Keun‐Wook, Hark Kyun Kim, Min‐Hee Ryu, et al.. (2023). Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.. Journal of Clinical Oncology. 41(4_suppl). 401–401. 2 indexed citations
6.
7.
Suh, Koung Jin, Min‐Hee Ryu, Dae Young Zang, et al.. (2023). AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20). The Oncologist. 28(9). e823–e834. 12 indexed citations
8.
9.
Zang, Dae Young, Hye Sook Han, Bum Jun Kim, et al.. (2021). Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. Journal of Clinical Oncology. 39(15_suppl). 4056–4056. 1 indexed citations
10.
Sohn, Sung‐Hwa, Semin Lee, Bum Jun Kim, et al.. (2021). An integrated mRNA–microRNA regulatory network identified INHBA and has-miR-135a-5p as predictors of gastric cancer recurrence. Molecular & Cellular Toxicology. 17(2). 213–220. 4 indexed citations
11.
Zang, Dae Young, et al.. (2020). Tepotinib inhibits the epithelial-mesenchymal transition and tumor growth of gastric cancers via increasing GSK3β, ECAD, MUC5AC, and MUC6.. Journal of Clinical Oncology. 38(15_suppl). e16562–e16562. 1 indexed citations
12.
Kim, Jung Han, Hyeong Su Kim, Bum Jun Kim, et al.. (2018). Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. Journal of Cancer. 9(22). 4279–4286. 35 indexed citations
13.
Zangari, Maurizio, Hanna Yoo, Bum Jun Kim, et al.. (2018). Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice. Endocrinology. 159(4). 1561–1569. 4 indexed citations
14.
Hyung, Jaewon, Bum Jun Kim, Changhoon Yoo, et al.. (2018). Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. Cancer Research and Treatment. 51(3). 901–909. 19 indexed citations
15.
Kim, Bum Jun, Changhoon Yoo, Kyu‐pyo Kim, et al.. (2017). Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. British Journal of Cancer. 116(5). 561–567. 55 indexed citations
16.
Kim, Bum Jun, Jae Ho Jeong, Jung Han Kim, Hyeong Su Kim, & Hyun Joo Jang. (2017). The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. Oncotarget. 8(19). 31112–31118. 9 indexed citations
17.
Kim, Bum Jun, et al.. (2017). Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. Indian Journal of Hematology and Blood Transfusion. 33(4). 581–585. 9 indexed citations
18.
Kim, Jung Han, Bum Jun Kim, & Hyeong Su Kim. (2017). Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget. 8(43). 75478–75487. 27 indexed citations
19.
Kim, Jung Han, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang, & Jin Lee. (2017). Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. Oncotarget. 8(52). 90351–90357. 37 indexed citations
20.
Yoon, Donghoon, Bum Jun Kim, & Josef T. Prchal. (2008). Cre recombinase expression controlled by the hematopoietic regulatory domain of Gata-1 is erythroid-specific. Blood Cells Molecules and Diseases. 40(3). 381–387. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yiyi Yu Breakdown of academic impact, for papers by Caterina Vivaldi Breakdown of academic impact, for papers by Xinyu Bi Breakdown of academic impact, for papers by Dongmei Ji Breakdown of academic impact, for papers by Alfredo Mellano Breakdown of academic impact, for papers by Dulabh Monga Breakdown of academic impact, for papers by Ho-Yeong Lim Breakdown of academic impact, for papers by Yusuke Mitsunori Breakdown of academic impact, for papers by Marlies Michl Breakdown of academic impact, for papers by Yun-shan Tan
Rankless by CCL
2026